ATE406176T1 - Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten - Google Patents

Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten

Info

Publication number: ATE406176T1
Authority: AT; Austria
Prior art keywords: inhibitor; treatment; combination therapy; mediated diseases; methotrexate
Prior art date: 1996-12-06

Application number

AT97954087T

Other languages

English (en)

Inventor

Alison Bendele

Regina Sennello

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-06

Filing date

1997-12-08

Publication date

2008-09-15

1997-12-08 Application filed by Amgen Inc filed Critical Amgen Inc

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406176T1 publication Critical patent/ATE406176T1/de

Links

102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 title abstract 4
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 title abstract 4
238000002648 combination therapy Methods 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 3
229960000485 methotrexate Drugs 0.000 abstract 3
-1 2,4-diamino-6-pteridinyl Chemical group 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
229960002989 glutamic acid Drugs 0.000 abstract 1
102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)

AT97954087T 1996-12-06 1997-12-08 Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten ATE406176T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US3279096P	1996-12-06	1996-12-06
US3635397P	1997-01-23	1997-01-23
US3931197P	1997-02-07	1997-02-07
US5202597P	1997-07-09	1997-07-09

Publications (1)

Publication Number	Publication Date
ATE406176T1 true ATE406176T1 (de)	2008-09-15

Family

ID=27488035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97954087T ATE406176T1 (de)	1996-12-06	1997-12-08	Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten

Country Status (9)

Country	Link
US (3)	US20030072756A1 (de)
EP (2)	EP2002846B1 (de)
JP (3)	JP4771563B2 (de)
AT (1)	ATE406176T1 (de)
AU (1)	AU736876B2 (de)
CA (1)	CA2273852C (de)
DE (1)	DE69738948D1 (de)
ES (2)	ES2615357T3 (de)
WO (1)	WO1998024477A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7091181B2 (en)	1994-12-12	2006-08-15	Omeros Corporation	Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
ES2615357T3 (es) *	1996-12-06	2017-06-06	Amgen Inc.	Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6927044B2 (en) *	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
US7067144B2 (en)	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
DK2319928T3 (da)	1998-10-23	2013-06-24	Kirin Amgen Inc	Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
WO2000056298A2 (en) *	1999-03-19	2000-09-28	Luitpold Pharmaceuticals, Inc.	Treatment of lyme disease with polysulfated glycosaminoglycan formulations
EP1200127B1 (de) *	1999-07-21	2008-06-25	Omeros Corporation	Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US6544504B1 (en)	1999-07-28	2003-04-08	Schering Corporation	Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU6376700A (en) *	1999-07-28	2001-02-19	Schering Corporation	Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
EP1095661A1 (de) *	1999-11-01	2001-05-02	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Vorbeugung und Behandlung von Infektionen assoziiert mit Biomaterialien
US6808902B1 (en) *	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP2003533187A (ja) *	2000-05-03	2003-11-11	アムジエン・インコーポレーテツド	治療薬としてのＦｃドメインを含む修飾ペプチド
US7087224B2 (en) *	2000-10-31	2006-08-08	Amgen Inc.	Method of treating anemia by administering IL-1ra
DE10132308A1 (de) *	2001-07-06	2003-01-30	Aventis Behring Gmbh	Kombinationspräparat zur Therapie von immunologischen Erkrankungen
MXPA04011470A (es)	2002-05-21	2005-02-14	Amgen Inc	Compuestos heterociclicos sustituidos y metodos de uso.
US7553827B2 (en)	2003-08-13	2009-06-30	Depuy Spine, Inc.	Transdiscal administration of cycline compounds
US7344716B2 (en)	2003-05-13	2008-03-18	Depuy Spine, Inc.	Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en)	2003-05-13	2008-09-30	Depuy Spine, Inc.	Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en)	2003-05-13	2012-09-25	Depuy Spine, Inc.	Autologous treatment of degenerated disc with cells
US8361467B2 (en) *	2003-07-30	2013-01-29	Depuy Spine, Inc.	Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en)	2003-11-26	2014-11-25	DePuy Synthes Products, LLC	Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CN101103045B (zh)	2004-09-24	2015-11-25	安姆根有限公司	修饰的Fc分子
US20070270431A1 (en) *	2004-09-29	2007-11-22	Kowa Co., Ltd.	Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
WO2006059108A2 (en) *	2004-12-02	2006-06-08	Domantis Limited	ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2006076673A2 (en) *	2005-01-14	2006-07-20	Regeneron Pharmaceuticals, Inc.	Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
US20090018121A1 (en) *	2005-03-29	2009-01-15	Kowa Co., Ltd.	Preventive and/or therapeutic agent for rheumatoid arthritis
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
EP1920772A4 (de) *	2005-08-31	2010-11-17	Kowa Co	Prophylaktisches und/oder therapeutisches verfahren für rheumatoide arthritis
JPWO2007049732A1 (ja) *	2005-10-28	2009-04-30	興和株式会社	関節リウマチの予防及び／又は治療法
CA2629850A1 (en) *	2005-12-01	2007-06-07	Domantis Limited	Competitive domain antibody formats that bind interleukin 1 receptor type 1
US20090203701A1 (en) *	2006-06-29	2009-08-13	Kowa Co., Ltd	Prophylactic and/or therapeutic agent for rheumatoid arthritis
US10105441B2 (en) *	2007-08-16	2018-10-23	The Schepens Eye Research Institute, Inc.	Method for inhibiting or reducing dry eye disease by IL-1Ra
US8986696B2 (en)	2007-12-21	2015-03-24	Depuy Mitek, Inc.	Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
PL2259774T3 (pl)	2008-02-27	2013-04-30	Biomet Biologics Llc	Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8753690B2 (en) *	2008-02-27	2014-06-17	Biomet Biologics, Llc	Methods and compositions for delivering interleukin-1 receptor antagonist
TW201113525A (en) *	2009-08-20	2011-04-16	Anchen Lab Inc	Methods for diagnosing diabetes and determining effectiveness of treatments
EP2470162B1 (de)	2009-08-27	2019-03-27	Biomet Biologics, LLC	Implantierbare vorrichtung zur herstellung von interleukin-1-rezeptor-antagonisten
CN107337735B (zh)	2010-07-29	2021-06-22	巴扎德制药公司	嵌合il-1受体i型激动剂和拮抗剂
WO2012078101A1 (en) *	2010-12-07	2012-06-14	Swedish Orphan Biovitrum Ab (Publ)	Method for the treatment of il-1 mediated diseases
JP2014522868A (ja) *	2011-07-29	2014-09-08	イレブン・バイオセラピユーテイクス・インコーポレイテツド	精製タンパク質
PL2968468T3 (pl)	2013-03-13	2021-12-20	Buzzard Pharmaceuticals AB	Preparaty chimerycznej cytokiny do dostarczania do oka
US9758806B2 (en)	2013-03-15	2017-09-12	Biomet Biologics, Llc	Acellular compositions for treating inflammatory disorders
US10208095B2 (en)	2013-03-15	2019-02-19	Biomet Manufacturing, Llc	Methods for making cytokine compositions from tissues using non-centrifugal methods
US20140271589A1 (en) *	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en)	2013-03-15	2018-01-30	Biomet Biologics, Llc	Treatment of inflammatory respiratory disease using biological solutions
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2512572A (en)		1950-06-20		Substituted pteridines and method
US3989703A (en)	1974-03-22	1976-11-02	Institutul Oncologic	Process of preparing N[p-{[(2,4-diamino-6-pteridyl)-methyl]N10 -methylamino}-benzoyl]-glutamic acid
US3892801A (en)	1974-09-11	1975-07-01	American Cyanamid Co	Method for preparing alkali salts of p-methylaminobenzoylglutamic acid
US4079056A (en)	1975-03-31	1978-03-14	The United States Of America As Represented By The Department Of Health, Education And Welfare	Method of making pteridine compounds
US4057548A (en)	1975-11-11	1977-11-08	Jacek Wiecko	Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor
US4067867A (en)	1976-03-30	1978-01-10	Jacek Wiecko	Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof
US4080325A (en)	1976-11-17	1978-03-21	The United States Of America As Represented By The Department Of Health, Education And Welfare	Synthesis of methotrexate
CH630380A5 (de)	1977-08-12	1982-06-15	Lonza Ag	Verfahren zur herstellung von l-methotrexat.
US4136101A (en)	1978-02-03	1979-01-23	American Cyanamid Company	Process for preparing dialkyl (p-aminobenzoyl) glutamates
US4306064A (en)	1980-03-25	1981-12-15	Ellard James A	Synthesis of 2,4-diamino-6-hydroxymethylpteridine
US4421913A (en)	1980-04-23	1983-12-20	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester
US4374987A (en)	1980-08-14	1983-02-22	American Cyanamid Company	Process for the preparation of high purity methotrexate and derivatives thereof
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
EP0154316B1 (de)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4716224A (en)	1984-05-04	1987-12-29	Seikagaku Kogyo Co. Ltd.	Crosslinked hyaluronic acid and its use
SE442820B (sv)	1984-06-08	1986-02-03	Pharmacia Ab	Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
US4863907A (en)	1984-06-29	1989-09-05	Seikagaku Kogyo Co., Ltd.	Crosslinked glycosaminoglycans and their use
US4582865A (en)	1984-12-06	1986-04-15	Biomatrix, Inc.	Cross-linked gels of hyaluronic acid and products containing such gels
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4605691A (en)	1984-12-06	1986-08-12	Biomatrix, Inc.	Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en)	1984-12-06	1987-01-13	Biomatrix, Inc.	Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv)	1985-03-01	1986-09-02	Pharmacia Ab	Format alster och forfarande for dess framstellning
US4713448A (en)	1985-03-12	1987-12-15	Biomatrix, Inc.	Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5202431A (en)	1985-07-08	1993-04-13	Fidia, S.P.A.	Partial esters of hyaluronic acid
US4851521A (en)	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
JPS6291197A (ja)	1985-10-17	1987-04-25	Dainippon Pharmaceut Co Ltd	抗ヒトインタ−ロイキン１抗体，その製法及びその使用法
FR2590255B1 (fr)	1985-11-19	1987-12-24	Rhone Poulenc Sante	Procede de preparation de derives de la pteridine
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
US5359032A (en) *	1987-08-26	1994-10-25	Biogen Inc.	Interkeukin-1 inhibitor
IL83878A (en)	1987-09-13	1995-07-31	Yeda Res & Dev	Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en)	1991-05-07	1992-06-21	Yeda Res & Dev	Pharmaceutical compositions comprising an anticytokyne
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en)	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US4968607A (en) *	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
WO1989004838A1 (en)	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
US5319071A (en)	1987-11-25	1994-06-07	Immunex Corporation	Soluble interleukin-1 receptors
GB8807803D0 (en)	1988-03-31	1988-05-05	Glaxo Group Ltd	Biochemical product
JPH02503867A (ja)	1988-04-15	1990-11-15	プロテイン　デザイン　ラブズ　インコーポレーテッド	Ｉｌ‐２レセプター特異的キメラ抗体
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
IL94039A (en)	1989-08-06	2006-09-05	Yeda Res & Dev	Antibodies to tbp - 1 and their use
EP0364778B1 (de)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Antikörper gegen Interleukin-1-beta
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US4957774A (en)	1988-12-14	1990-09-18	Canon Kabushiki Kaisha	Method of heat-fixing toner image
JP2989002B2 (ja)	1988-12-22	1999-12-13	キリン―アムジエン・インコーポレーテツド	化学修飾顆粒球コロニー刺激因子
US5041554A (en) *	1989-01-31	1991-08-20	Merrell Dow Pharmaceuticals Inc.	Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
ATE289350T1 (de)	1989-04-21	2005-03-15	Amgen Inc	Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de)	1989-05-09	1990-12-13	Basf Ag	Neue proteine und ihre herstellung
ATE119942T1 (de)	1989-05-18	1995-04-15	Yeda Res & Dev	Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
US5356883A (en)	1989-08-01	1994-10-18	Research Foundation Of State University Of N.Y.	Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
AU630497B2 (en)	1989-09-05	1992-10-29	Immunex Corporation	Tumor necrosis factor-alpha and -beta receptors
US5395760A (en)	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de)	1989-09-12	2006-11-23	Ahp Mfg B V	TFN-bindende Proteine
JPH03127800A (ja)	1989-10-13	1991-05-30	Teijin Ltd	腫瘍壊死因子活性抑制物質
AU651955B2 (en)	1989-11-29	1994-08-11	Amgen, Inc.	Production of recombinant human interleukin-1 inhibitor
AU642938B2 (en)	1989-12-13	1993-11-04	Yeda Research And Development Co. Ltd.	Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5272071A (en)	1989-12-22	1993-12-21	Applied Research Systems Ars Holding N.V.	Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5136021A (en)	1990-02-27	1992-08-04	Health Research, Inc.	TNF-inhibitory protein and a method of production
AU649245B2 (en) *	1990-04-02	1994-05-19	Amgen, Inc.	Methods for treating interleukin-1 mediated diseases
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US6458360B1 (en)	1990-04-25	2002-10-01	The Johns Hopkins University	Soluble complement regulatory molecules
WO1991017184A1 (en)	1990-04-27	1991-11-14	The Upjohn Company	Modified interleukin-1 inhibitors
EP0534978B1 (de) *	1990-05-01	1999-03-24	Chiron Corporation	Interleukin-i antagonist und seine verwendung
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
GB2246569A (en)	1990-06-15	1992-02-05	Charing Cross Sunley Research	Tumour necrosis factor - alpha binding protein
DK0835939T3 (da)	1990-06-28	2006-03-13	Sanofi Aventis Deutschland	Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
WO1992001002A1 (en)	1990-07-11	1992-01-23	Teijin Limited	Tumor necrosis factor activity inhibitor and production thereof
ATE130049T1 (de)	1990-07-13	1995-11-15	Transkaryotic Therapies Inc	Verfahren zum absuchen einer bibliothek.
US5932537A (en) *	1990-10-09	1999-08-03	Chiron Corporation	Method for attenuating a cellular response to IL-1
US5858355A (en)	1990-12-20	1999-01-12	University Of Pittsburgh Of The Commonwealth System Of Higher Education	IRAP gene as treatment for arthritis
CA2100329C (en)	1991-01-18	2009-09-29	David F. Carmichael	Methods for treating tumor necrosis factor mediated diseases
DE69233069T2 (de)	1991-03-15	2003-11-27	Amgen Inc., Thousand Oaks	Pegylation von polypeptiden
GR920100122A (el)	1991-04-05	1993-03-16	Ethicon Inc	Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
DE69233441T2 (de)	1991-04-26	2005-10-13	Osaka Bioscience Institute, Suita	Menschliches Zelloberflächen-Antigen codierende DNA
WO1993003183A1 (en)	1991-08-02	1993-02-18	Transkaryotic Therapies, Inc.	Library screening method
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en)	1991-10-15	1993-04-29	Mullarkey Michael F	Methods and compositions for treating allergic reactions
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
CA2130762C (en)	1994-08-24	1999-07-06	Eva Anne Turley	Treatment of disease and conditions associated with macrophage infiltration
AU671116B2 (en)	1992-03-30	1996-08-15	Immunex Corporation	Fusion proteins comprising tumor necrosis factor receptor
JPH07509223A (ja)	1992-04-30	1995-10-12	アムジェンインコーポレイテッド	インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja)	1992-05-08	1993-11-22	Nissan Motor Co Ltd	シフトレバー装置
DE4219626A1 (de)	1992-06-16	1993-12-23	Wehling Peter Priv Doz Dr Med	Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
JPH0630788A (ja)	1992-07-16	1994-02-08	Otsuka Pharmaceut Co Ltd	ヒトインターロイキン−１に対する組換え抗体
NZ256328A (en)	1992-09-17	1997-06-24	Amgen Boulder Inc	Pharmaceutical compositions of interleukin-1 inhibitor and non-ionic surfactant or viscosity enhancer
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5340572A (en) *	1993-02-08	1994-08-23	Insite Vision Incorporated	Alkaline ophthalmic suspensions
JPH08511507A (ja)	1993-03-08	1996-12-03	ユニバーシティーオブピッツバーグオブザコモンウェルスシステムオブハイヤーエデュケーション	哺乳動物宿主の結合組織を処置するための遺伝子導入
EP0689449B1 (de)	1993-03-19	2002-10-30	Vacsyn S.A.	Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin
US6326353B1 (en)	1993-03-23	2001-12-04	Sequus Pharmaceuticals, Inc.	Enhanced circulation effector composition and method
FR2706772A1 (en)	1993-06-22	1994-12-30	Vacsyn Sa	Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5508262A (en) *	1993-12-15	1996-04-16	University Of South Florida	Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
IT1269989B (it)	1994-09-21	1997-04-16	Dompe Spa	Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
IT1270662B (it) *	1994-10-13	1997-05-07	Applied Research Systems	Antagonista della interleuchina-1
TW313568B (de)	1994-12-20	1997-08-21	Hoffmann La Roche
US5690961A (en)	1994-12-22	1997-11-25	Hercules Incorporated	Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
AU705281B2 (en)	1994-12-23	1999-05-20	Uab Research Foundation	Secreted human fas antigen
US5723116A (en) *	1995-01-06	1998-03-03	University Of South Florida	Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
PE64396A1 (es)	1995-01-23	1997-01-28	Hoffmann La Roche	Proteina accesoria del receptor de la interleucina 1
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6096728A (en) *	1996-02-09	2000-08-01	Amgen Inc.	Composition and method for treating inflammatory diseases
DE69739656D1 (de)	1996-02-09	2009-12-31	Amgen Inc	1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2615357T3 (es) *	1996-12-06	2017-06-06	Amgen Inc.	Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
US5968607A (en) *	1997-12-10	1999-10-19	Chromium Graphics	Device and method for etch and emboss process printing

1997
- 1997-12-08 ES ES08014990.9T patent/ES2615357T3/es not_active Expired - Lifetime
- 1997-12-08 AT AT97954087T patent/ATE406176T1/de not_active IP Right Cessation
- 1997-12-08 WO PCT/US1997/022720 patent/WO1998024477A1/en not_active Ceased
- 1997-12-08 DE DE69738948T patent/DE69738948D1/de not_active Expired - Lifetime
- 1997-12-08 CA CA002273852A patent/CA2273852C/en not_active Expired - Lifetime
- 1997-12-08 EP EP08014990.9A patent/EP2002846B1/de not_active Expired - Lifetime
- 1997-12-08 AU AU57955/98A patent/AU736876B2/en not_active Expired
- 1997-12-08 ES ES97954087T patent/ES2312179T3/es not_active Expired - Lifetime
- 1997-12-08 JP JP52589298A patent/JP4771563B2/ja not_active Expired - Lifetime
- 1997-12-08 EP EP97954087A patent/EP0949931B1/de not_active Expired - Lifetime
2002
- 2002-10-04 US US10/265,037 patent/US20030072756A1/en not_active Abandoned
2003
- 2003-07-16 US US10/621,784 patent/US20040044001A1/en not_active Abandoned
2006
- 2006-07-31 JP JP2006209209A patent/JP2006306890A/ja not_active Withdrawn
2008
- 2008-08-29 JP JP2008222907A patent/JP2009007380A/ja not_active Withdrawn
2009
- 2009-02-27 US US12/380,535 patent/US20090203609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2312179T3 (es)	2009-02-16
ES2615357T3 (es)	2017-06-06
CA2273852A1 (en)	1998-06-11
US20040044001A1 (en)	2004-03-04
JP2006306890A (ja)	2006-11-09
EP2002846B1 (de)	2017-01-25
WO1998024477A1 (en)	1998-06-11
EP2002846A3 (de)	2009-01-14
EP0949931B1 (de)	2008-08-27
CA2273852C (en)	2009-09-29
EP0949931A1 (de)	1999-10-20
AU5795598A (en)	1998-06-29
JP2009007380A (ja)	2009-01-15
DE69738948D1 (de)	2008-10-09
JP4771563B2 (ja)	2011-09-14
JP2002509529A (ja)	2002-03-26
AU736876B2 (en)	2001-08-02
HK1023501A1 (en)	2000-09-15
EP2002846A2 (de)	2008-12-17
US20090203609A1 (en)	2009-08-13
US20030072756A1 (en)	2003-04-17

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE406176T1 (de)	2008-09-15	Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
DE69327582D1 (de)	2000-02-17	Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
ATE184792T1 (de)	1999-10-15	2-bromomelatonin zur behandlung von schlafstörungen
WO1998024463A3 (en)	1998-07-16	Combination therapy using a tnf binding protein for treating tnf-mediated diseases
RU94046424A (ru)	1997-03-10	Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
NZ248377A (en)	2000-01-28	Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
ATE334668T1 (de)	2006-08-15	Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE69826695D1 (de)	2004-11-04	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE60227658D1 (de)	2008-08-28	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
EP0787802A3 (de)	1997-08-27
ATE91628T1 (de)	1993-08-15	Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
NO307645B1 (no)	2000-05-08	Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
DE59007531D1 (de)	1994-12-01	Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen.
DE69521536D1 (de)	2001-08-09	Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
ATE99932T1 (de)	1994-01-15	Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE133859T1 (de)	1996-02-15	Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen
BR9809678A (pt)	2000-07-11	Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ES555118A0 (es)	1988-07-16	Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
ATE113478T1 (de)	1994-11-15	Verwendung antigener substanzen zur prophylaxe oder therapie von störungen und krankheiten im verdauungstrakt von tieren und menschen.
DK0643585T3 (da)	2000-05-08	Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
DK347289D0 (da)	1989-07-13	Terapeutiske forbindelser
EP0373771A3 (de)	1990-11-14	Neue pharmazeutische Anwendungen von Cystatinen
DE69307702D1 (de)	1997-03-06	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69118847D1 (de)	1996-05-23	Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
EP1352656A3 (de)	2004-02-04	Kombinationtherapie mit einem tnf-bindendem Protein zür behandlung von durch tnf verursachten Erkrangungen